Cargando…

Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: A case-control test-negative design study

BACKGROUND: Vaccination with the 23-valent pneumococcal polysaccharide vaccine (PPV23) is available in the United Kingdom to adults aged 65 years or older and those in defined clinical risk groups. We evaluated the vaccine effectiveness (VE) of PPV23 against vaccine-type pneumococcal pneumonia in a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lawrence, Hannah, Pick, Harry, Baskaran, Vadsala, Daniel, Priya, Rodrigo, Chamira, Ashton, Deborah, Edwards-Pritchard, Rochelle C., Sheppard, Carmen, Eletu, Seyi D., Litt, David, Fry, Norman K., Rose, Samuel, Trotter, Caroline, McKeever, Tricia M., Lim, Wei Shen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584218/ https://www.ncbi.nlm.nih.gov/pubmed/33095759 http://dx.doi.org/10.1371/journal.pmed.1003326

Ejemplares similares

Non-invasive pneumococcal pneumonia due to vaccine serotypes: A systematic review and meta-analysis
por: Lansbury, Louise, et al.
Publicado: (2022)

Does the rise in seasonal respiratory viruses foreshadow the return of invasive pneumococcal disease this winter?
por: Amin-Chowdhury, Zahin, et al.
Publicado: (2022)

Increased incidence of adult pneumococcal pneumonia during school holiday periods
por: Daniel, Priya, et al.
Publicado: (2017)

Evolution of pneumococcal serotype epidemiology in Botswana following introduction of 13-valent pneumococcal conjugate vaccine
por: Patel, Sweta M., et al.
Publicado: (2022)

Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001
por: Leach, Amanda J, et al.
Publicado: (2009)

Periodic cycles of pneumococcal serotypes carried by children before and after 7-valent pneumococcal conjugate vaccine
por: Paulo, Ana Cristina, et al.
Publicado: (2017)

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults
por: Shiramoto, Masanari, et al.
Publicado: (2015)

1373. Vaccine Effectiveness and Pneumococcal Serotypes in Pediatric Otitis Media in the Era of Routine 13-valent Pneumococcal Vaccination in the United States
por: Hulten, Kristina G, et al.
Publicado: (2020)

A Review of the Impact of Pneumococcal Polysaccharide Conjugate Vaccine (7-valent) on Pneumococcal Meningitis
por: Tin Tin Htar , Myint, et al.
Publicado: (2013)

2707. Non 13-Valent Pneumococcal Conjugate Vaccine Serotypes Predominate as Causes of Pneumococcal Otitis Media in Children
por: Hulten, Kristina G, et al.
Publicado: (2019)

Estimates of the Health and Economic Burden of Pneumococcal Infections Attributable to the 15-Valent Pneumococcal Conjugate Vaccine Serotypes in the USA
por: Owusu-Edusei, Kwame, et al.
Publicado: (2022)

Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe
por: Hanquet, Germaine, et al.
Publicado: (2022)

Pneumococcal carriage in children and their household contacts six years after introduction of the 13-valent pneumococcal conjugate vaccine in England
por: Southern, Jo, et al.
Publicado: (2018)

Comparison of immunogenicity and safety of an influenza vaccine administered concomitantly with a 13-valent pneumococcal conjugate vaccine or 23-valent polysaccharide pneumococcal vaccine in the elderly
por: Seo, Yu Bin, et al.
Publicado: (2017)

Correction to: Estimates of the Health and Economic Burden of Pneumococcal Infections Attributable to the 15-Valent Pneumococcal Conjugate Vaccine Serotypes in the USA
por: Owusu-Edusei, Kwame, et al.
Publicado: (2022)

Increased Incidence of Invasive Pneumococcal Disease among Children after COVID-19 Pandemic, England
por: Bertran, Marta, et al.
Publicado: (2022)

Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults
por: Schmoele-Thoma, Beate, et al.
Publicado: (2019)

Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
por: Malene B, Mikkelsen, et al.
Publicado: (2023)

A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult
por: Ngamprasertchai, Thundon, et al.
Publicado: (2023)

Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine and Changes in Invasive Pneumococcal Disease Incidence from 2000 to 2017 in Those Aged 65 and Over in England and Wales
por: Djennad, Abdelmajid, et al.
Publicado: (2019)

Effectiveness of 23-valent pneumococcal polysaccharide vaccine on diabetic elderly
por: Kuo, Chia-Sheng, et al.
Publicado: (2016)

Serotype-specific effectiveness against pneumococcal carriage and serotype replacement after ten-valent Pneumococcal Conjugate Vaccine (PCV10) introduction in Pakistan
por: Nisar, Muhammad Imran, et al.
Publicado: (2022)

Invasive Pneumococcal Disease and 7-Valent Pneumococcal Conjugate Vaccine, the Netherlands
por: van Deursen, Anna M.M., et al.
Publicado: (2012)

Decrease in Pneumococcal Co-Colonization following Vaccination with the Seven-Valent Pneumococcal Conjugate Vaccine
por: Valente, Carina, et al.
Publicado: (2012)

Indirect effect of 7-valent and 13-valent pneumococcal conjugated vaccines on pneumococcal pneumonia hospitalizations in elderly
por: Kislaya, Irina, et al.
Publicado: (2019)

The 15-valent pneumococcal conjugate vaccine V114 induces cross-reactive antibodies against pneumococcal serotype 6C
por: Shi, Yaru, et al.
Publicado: (2023)

Systematic Literature Review of the Epidemiological Characteristics of Pneumococcal Disease Caused by the Additional Serotypes Covered by the 20-Valent Pneumococcal Conjugate Vaccine
por: Méroc, Estelle, et al.
Publicado: (2023)

Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in Greenland
por: Nikolova, Kristiana Alexandrova, et al.
Publicado: (2021)

The impact of introduction of the 10-valent pneumococcal conjugate vaccine on pneumococcal carriage in Nigeria
por: Adamu, Aishatu L., et al.
Publicado: (2023)

Effect of 23-valent pneumococcal polysaccharide vaccine on medical expenses in Japan
por: Satomura, Kazunari, et al.
Publicado: (2014)

Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Adults with and without Immunosuppressive Therapy
por: Garcia Garrido, Hannah M., et al.
Publicado: (2022)

576. Burden of Pneumococcal Disease Due to Serotypes Covered by the 13-Valent and New Higher-Valent Pneumococcal Conjugate Vaccines in All Children and Children at Risk in the United States
por: Huang, Liping, et al.
Publicado: (2022)

1730. Increasing Vaccination Rates of 23-valent Pneumococcal Polysaccharide Vaccine Among Patients at High-Risk for Invasive Pneumococcal Disease
por: Lyon, Edward, et al.
Publicado: (2023)

Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia
por: Haggenburg, Sabine, et al.
Publicado: (2023)

Risk factors for serotype 19A carriage after introduction of 7-valent pneumococcal vaccination
por: Cohen, Robert, et al.
Publicado: (2011)

Clonal Expansion within Pneumococcal Serotype 6C after Use of Seven-Valent Vaccine
por: Loman, Nicholas J., et al.
Publicado: (2013)

In-Hospital Pneumococcal Polysaccharide Vaccination Is Associated With Detection of Pneumococcal Vaccine Serotypes in Adults Hospitalized for Community-Acquired Pneumonia
por: Grijalva, Carlos G., et al.
Publicado: (2015)

Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older
por: Vila-Corcoles, Angel, et al.
Publicado: (2010)

Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine against Invasive Pneumococcal Disease in Adults, Japan, 2013–2017
por: Shimbashi, Reiko, et al.
Publicado: (2020)

Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis
por: Rozenbaum, Mark H, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_2j8a68pa70vfojbhoueftn8cj1